Olink(US:OLK) Newsfilter·2024-06-06 06:00Core Insights - Olink Holding AB has launched the Olink Target 48 Immune Surveillance, a multiplexed protein assay panel designed for detailed monitoring of the immune system in clinical research [1] - The assay allows detection and quantification of up to 44 biomarkers from just 1μL of sample, and when combined with the Olink Target 48 Cytokine panel, it can analyze up to 89 immune-related proteins using only 2μL [2] - The new product aims to enhance research capabilities in areas such as inflammation, immune response, immuno-oncology, and infectious diseases [2] Product Development and Technology - The Olink Target 48 Immune Surveillance utilizes Olink's PEA™ technology, ensuring high-quality control and validation [3] - The product has been developed in collaboration with the research community to continuously improve its performance [3] Expert Opinions - Experts from the Broad Institute and Massachusetts General Hospital have expressed that the new panels will provide precise quantitative data for analyzing biological pathways and predictive biomarkers, facilitating future oncology trials [4] Global Reach and Research Acceleration - The Olink Target 48 Immune Surveillance is designed to overcome import barriers, streamlining workflows and minimizing maintenance for laboratories [5] - It is compatible with the Olink® Signature Q100 system, enhancing research efficiency through powerful quality control and statistical analysis [5] Strategic Vision - The introduction of this panel is part of Olink's broader portfolio aimed at advancing proteomics solutions across various stages of drug development and disease characterization [7] - The company emphasizes its commitment to precision medicine and the potential of its solutions to provide insights into therapeutic responses and disease progression [6]